DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Market Access Disease Navigator | Oncology
Views on disease-specific dynamics influencing patient access to inform contracting, reimbursement, account, marketing, and sales strategies.

Market access dynamics impacting oncology are growing more complex as shifts in the provider and payer landscape drive change

  • Hospital ownership
  • Provider consolidation
  • Oncology mega networks
  • Cost and complexity of emerging treatments
  • Value-based payment models
  • Drug purchasing behavior

How much are these factors impacting access to and utilization of your
therapy?

Do you have the necessary resources to efficiently navigate these quickly evolving market access dynamics?

Market Access Disease Navigator
Better understand market access dynamics impacting oncology

Market Access Disease Navigator utilizes pharmacy and medical claims data from DRG’s Real World Data Repository and local market expertise to provide disease specific, account-level insights into local population demographics; patients’ access to established and emerging therapies; provider control over treatment decisions; and underlying payment dynamics that can drive care delivery, quality, and cost.

Patient Population
Insight into percentage of patients by oncology indication based on claims data, key demographics, disease incidence rates, and risk factors for cancer in the surrounding geography

Access
Details on physicians by specialty providing care, sites of care, geographic presence, clinical trials, and emerging treatment capabilities such as immunotherapy (including CAR-T cell therapy)

Control
Analysis of clinical pathways, clinical integration, EMR technology, drug purchasing strategy, membership in regional/national networks, and key leaders

Payment
Assessment of payer share and policies, value-based care models, community versus hospital-based practice, 340B status, and PPS exemptions

Powerful Analysis Allows you to:

  • Develop engagement strategies and allocate resources by taking into account unique characteristics and clinical capabilities of major oncology provider practices
  • Segment oncology provider groups based on level of control in terms of clinical integration, influence over treatment decisions and participation in mega networks
  • Gauge the impact of value-based payment models and payer dynamics influencing oncology providers and their clinical practices